Oral agents and Outpatient Injections
FUNDING:
Medications that are taken at home may be covered by the provincial drug benefit plan or by private insurance plans.
FORMULARIES:
RAMQ List of Medications: Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. Generic | mCRPC | 250 mg PO / 500 mg PO |
Multiple |
Exceptional medication with recognized indications for payment Eligibility1:
Notes1:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Abiraterone (Zytiga) Janssen Inc. Generic | mCSPC | - |
- |
No listing as of Mar. 2022 |
- |
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Alendronate Generic | Osteoporosis | 5 mg PO | 10 mg PO | 70 mg PO |
Multiple |
|
|
Apotex: Access Here |
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
02478374 |
Exceptional medication Eligibility1: Patients with nmCRPC
Notes: The maximum duration of each authorization is four months When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect defined by the absence of disease progression **60 mg tablet funded, 240 mg tablet pending provincial funding decision |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
02478374 |
Exceptional medication Eligibility: In association with ADT, for the treatment of mCSPC, in persons:
Notes: The maximum duration of each authorization is four months When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect by the absence of disease progression. Apalutamide is not authorized following failure with an androgen synthesis inhibitor or a second-generation ARI if they have been administered to treat prostate cancer **60 mg tablet funded, 240 mg tablet pending provincial funding decision |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Darolutamide (Nubeqa) Bayer | nmCRPC | 300 mg PO |
02496348 |
Exceptional medication Eligibility:
Notes:
|
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email:
|
Darolutamide (Nubeqa) Bayer | mCSPC | 300 mg PO |
02496348 |
Exceptional medication Eligibility:
|
NUBEQA® DART Patient Support Program: Toll free:1-833-955-3278 Fax:1-877-208-4393 Email: info@dartsupport.ca |
|
Denosumab (Prolia) Amgen | Osteoporosis | S.C. Inj. Sol. (syr) 60 mg/ml |
02343541 |
Exceptional medication Eligibility1:
|
|
ProVital Program: Access Here |
Denosumab (Xgeva) Amgen | mCRPC + Bone mets | Inj. Sol. 120 mg /1.7mL |
02368153 |
Exceptional medication Eligibility1:
|
|
The VICTORY Program: Access Here |
Enzalutamide (Xtandi) Astellas | mCRPC | 40 mg PO |
02407329 |
Exceptional medication Eligibility1:
Notes1:
|
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Enzalutamide (Xtandi) Astellas | nmCRPC | 40 mg capsule |
02407329 |
For treatment of non-metastatic castration-resistant prostate cancer, in persons:
and
The maximum duration of each authorization is four months
When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect defined by the absence of disease progression |
RAMQ List of Exceptional Medications With Recognized Indications for Payment |
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
Enzalutamide (Xtandi) Astellas | mCSPC | 40 mg capsule |
02407329 |
In association with an androgen deprivation therapy (ADT), for treatment of metastatic castration-sensitive prostate cancer, in persons whose ECOG performance status is 0 or 1:
or
The maximum duration of each authorization is four months.
When requesting continuation of treatment, the physician must provide evidence of a beneficial clinical effect by the absence of disease progression.
It must be noted that enzalutamide is not authorized following failure with an androgen synthesis inhibitor or a second-generation androgen receptor inhibitor if they have been administered to treat prostate cancer. |
RAMQ List of Exceptional Medications With Recognized Indications for Payment |
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French) |
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | mCRPC | Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Access Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
Listed as of April 2022 Recognized indication for payment
Each authorization is for a maximum period of 4 months.
When requesting continuation of treatment, proof of a clinical benefit by the absence of disease progression must be provided. |
- |
AstraZeneca Patient Support Program: Access Here |